Physician profile
Christopher David Lowe
NPI 1831480524
$6,448.89
in general payments reported to CMS, 2019-2025
29 companies · $1,764 in 2025
The $1,764 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $233 · 2021: $31.02 · 2022: $702 · 2023: $1,609 · 2024: $1,881 · 2025: $1,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,154 · Education: $99.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,154.11 |
| Education | $99.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,226.78 | 2019-2025 | |
| Lilly USA, LLC | $802.44 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $642.18 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $605.82 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $516.42 | 2020-2025 | Ilumya, Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $440.36 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Genzyme Corporation | $296.60 | 2022-2025 | |
| Ucb, INC. | $271.95 | 2020-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $266.07 | 2022-2025 | Opzelura |
| Dermavant Sciences, INC. | $222.70 | 2023-2024 | Vtama |
| Amgen INC. | $189.78 | 2023-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $136.85 | 2022-2025 | Sotyktu |
| Pfizer INC. | $132.85 | 2020-2025 | |
| Galderma Laboratories, L.P. | $120.45 | 2019-2025 | Nemluvio, Epsolay, Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $103.94 | 2022-2023 | Targretin, Siliq, Duobrii |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $101.14 | 2022-2024 | |
| Organon LLC | $66.07 | 2025 | Vtama |
| Leo Pharma INC. | $50.08 | 2023-2024 | Adbry |
| Verrica Pharmaceuticals INC. | $41.29 | 2023-2024 | Ycanth |
| Almirall LLC | $39.20 | 2023 | Seysara |
| Biofrontera INC. | $36.32 | 2024-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Arcutis Biotherapeutics, INC. | $22.53 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $19.11 | 2024 | Simlandi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.06 | 2024 | Spevigo |
| Paratek Pharmaceuticals, INC. | $18.45 | 2023 | Nuzyra |
| Prugen, INC. Pharmaceuticals | $15.55 | 2020 | |
| Botanix Sb INC | $15.19 | 2025 | Sofdra |
| Smith+Nephew, INC. | $14.94 | 2024 | Collagenase Santyl |
| Strata Skin Sciences, INC. | $14.77 | 2024 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.